SUN-523 XLH Outcome Data from One Centre Experience with Burosumab
Sign Up to like & getrecommendations! Published in 2019 at "Journal of the Endocrine Society"
DOI: 10.1210/js.2019-sun-523
Abstract: Abstract X-linked hypophosphataemia (XLH) is a rare, genetic, chronically debilitating and deformative bone disease that profoundly impacts the affected individual’s day-to-day functioning and quality of life. High levels of circulating fibroblast growth factor 23 (FGF23)… read more here.
Keywords: one centre; mmol; week; xlh ... See more keywords